Skip to main content

Table 3 Increases in hemoglobin levels immediately before the onset of adverse events

From: Long-term safety and effectiveness of a continuous erythropoietin receptor activator (CERA) in patients with renal anemia: a prospective, observational, multicenter study

Types of AEs Disease stage Rate of increase in hemoglobin level immediately before onset of AEs (g/dL/week)
<− 0.5 ≥ − 0.5 and < − 0.3 ≥ − 0.3 and ≤ 0.3 >  0.3 and ≤ 0.5 > 0.5
Overall patients ND 161 370 1522 477 212
HD 155 419 1367 423 119
PD 43 138 330 153 71
All AEs ND 7 (4.34) 3 (0.81) 48 (3.15) 2 (0.41) 2 (0.94)
HD 1 (0.64) 2 (0.47) 64 (4.68) 7 (1.65) 1 (0.84)
PD 1 (2.32) 3 (2.17) 14 (4.24) 2 (1.30) 0 (0.00)
Vascular access thrombosis ND 1 (0.06)
HD 1 (0.23) 8 (0.58) 1 (0.23)
PD
Hypertension ND 21 (1.37) 1 (0.47)
HD 1 (0.23) 28 (2.04) 1 (0.23)
PD 2 (1.44) 8 (2.42) 2 (1.30)
Cardiovascular disease ND 4 (2.48) 2 (0.54) 21 (1.37) 2 (0.41) 1 (0.47)
HD 1 (0.64) 15 (1.09) 2 (0.47) 1 (0.84)
PD 1 (0.72) 6 (1.81)
Cerebral hemorrhage ND 1 (0.62) 1 (0.27) 3 (0.19)
HD 7 (0.51) 2 (0.47)
PD 1 (0.30)
Thromboembolism ND 2 (1.24) 5 (0.32)
HD 1 (0.23) 22 (1.60) 3 (0.70)
PD 1 (2.32) 1 (0.30)
  1. AEs adverse events, Hb hemoglobin, HD hemodialysis, ND not on dialysis, PD peritoneal dialysis